Search

Your search keyword '"Sonia, Burrel"' showing total 4 results
Start Over Author "Sonia, Burrel" Journal the journal of infection
4 results on '"Sonia, Burrel"'

1. The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

Author

Elisa Teyssou, Benoit Visseaux, Laurence Morand-Joubert, Vincent Calvez, Cathia Soulié, Aurélie Schnuriger, Charlotte Charpentier, Sidonie Lambert-Niclot, Stéphane Marot, Valentin Leducq, Marc Wirdern, Nadira Houhou-Fidouh, Basma Abdi, Sonia Burrel, Diane Descamps, Sophie Sayon, Anne-Geneviève Marcelin, Aude Jary, Karen Zafilaza, Valentine Marie Ferré, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Virologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Virologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Laboratoire de virologie [APHP Claude Bernard Bichat], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre National de Référence Herpèsvirus [CHU Pitié Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], and TEYSSOU, Elisa

Subjects
Microbiology (medical), Cycle threshold, 2019-20 coronavirus outbreak, variants, Coronavirus disease 2019 (COVID-19), business.industry, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], COVID-19, Newly diagnosed, Biology, Viral Load, Virology, Antibodies, Neutralizing, [SDV] Life Sciences [q-bio], Infectious Diseases, Medicine, Humans, business, Viral load, Letter to the Editor, 501Y.V1, ComputingMilieux_MISCELLANEOUS, 501Y.V2
Abstract

The 501Y.V2 and the 501Y.V1 SARS-CoV-2 variants emerged and spread rapidly into the world. We analysed the viral load of 643 nasopharyngeal samples of COVID-19 patients at diagnosis and found that the 501Y.V1 and the 501Y.V2 variants presented a viral load three to ten times and two times higher than the historical variants, respectively.HighlightsViral load in COVID-19 patient nasopharyngeal samples was different between variants.The 501Y.V2 variant had a viral load 2 times higher than the historical variantsThe 501Y.V2 variant had a viral load slightly lower than the 501Y.V1The 501Y.V1 variant had a viral load 3-10 times higher than the historical variants

Published
2021
Full Text
View/download PDF

2. Medical features of COVID-19 and influenza infection: A comparative study in Paris, France

Author

Sonia Burrel, Aude Jary, Hélène Faury, Marc Wirden, Vincent Calvez, Martin Dres, Anne-Geneviève Marcelin, Charles-Edouard Luyt, Basma Abdi, David Boutolleau, Pierre Hausfater, Valérie Pourcher, Mathilde Payen, Camille Courboulès, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), BIOSFAST [CHU Pitié-Salpêtrière] (GRC 14), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Neurophysiologie Respiratoire Expérimentale et Clinique (UMRS 1158), dres, martin, Service de virologie [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Urgences [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Neurophysiologie Respiratoire Expérimentale et Clinique, Service de Pneumologie et Réanimation Médicale [CHU Pitié-Salpêtrière] (Département ' R3S '), Gestionnaire, HAL Sorbonne Université 5, Service de Virologie [CHU Pitié-Salpêtrière], and Service d'Accueil des Urgences [CHU Pitié-Salpêtrière] (SAU)

Subjects
0301 basic medicine, Microbiology (medical), 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), [SDV]Life Sciences [q-bio], 030106 microbiology, Death risk, Overweight, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Diabetes mellitus, medicine, 030212 general & internal medicine, Risk factor, ComputingMilieux_MISCELLANEOUS, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, References: 10, business.industry, Mortality rate, COVID-19, medicine.disease, Influenza, 3. Good health, [SDV] Life Sciences [q-bio], Infectious Diseases, Respiratory failure, Risk factors, Severe clinical forms, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, medicine.symptom, business
Abstract

• COVID-19 and influenza patients share overweight as a risk factor for severe infection. • Higher death rate was reported in COVID-19 group than in influenza group. • COVID-19 patients developed preferentially secondary respiratory failure. • Older age and diabetes were confirmed as major contributing death risk factors in COVID-19.

Published
2020
Full Text
View/download PDF

3. Clinical presentation of Covid-19 in health care workers from a French University Hospital

Author

David Boutolleau, Vincent Calvez, Séverine Nguyen, Philippe Flandre, Martine Louet, Sonia Burrel, Stéphane Marot, Anne-Geneviève Marcelin, Agnès Chabouis, Aude Jary, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Flandre, Philippe

Subjects
Microbiology (medical), 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), media_common.quotation_subject, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Health Personnel, Pneumonia, Viral, MEDLINE, Article, Presentation, Betacoronavirus, [STAT.AP] Statistics [stat]/Applications [stat.AP], Pandemic, Health care, Medicine, Humans, Pandemics, media_common, [STAT.AP]Statistics [stat]/Applications [stat.AP], Infection Control, business.industry, SARS-CoV-2, COVID-19, University hospital, Infectious Diseases, Family medicine, business, Coronavirus Infections
Abstract

International audience; No abstract available

Published
2020
Full Text
View/download PDF

4. Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19

Author

Anne-Geneviève Marcelin, David Boutolleau, Vincent Calvez, Nagisa Godefroy, Sonia Burrel, Gilles Peytavin, Elise Klement-Frutos, Eric Caumes, Stéphane Marot, Valérie Pourcher, and Minh Patrick Lê

Subjects
0301 basic medicine, Oncology, Microbiology (medical), 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viruses, 030106 microbiology, Severe Acute Respiratory Syndrome, Antiviral Agents, Article, Disease Outbreaks, protease inhibitor, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, Internal medicine, medicine, Humans, Protease inhibitor (pharmacology), 030212 general & internal medicine, Prospective Studies, skin and connective tissue diseases, Letter to the Editor, Ritonavir, business.industry, SARS-CoV-2, fungi, virus diseases, COVID-19, Lopinavir, Pneumonia, Viral Load, biochemical phenomena, metabolism, and nutrition, virology, lopinavir, Infectious Diseases, pharmacology, business, Viral load, medicine.drug
Abstract

Highlights No specific treatment against SARS-CoV-2 is available after 6 months of COVID-19 worldwide outbreak Antivirals could decrease the viral load and reduce direct and indirect damages of SARSCoV-2 infection Ritonavir-bosted lopinavir is effective against SARS-CoV-2 in vitro Sequential virological and pharmacological monitoring helped to understand the efficacy of ritonavir-boosted lopinavir in a SARS-CoV-2 infected patient Ritonavir-boosted lopinavir could be proposed as early treatment for SARS-CoV-2 infection

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results